Commercialization, global expansion and product development progress
strengthen market leadership
WINNIPEG, Aug. 14 /CNW/ - IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company")
today reported its financial results for the second quarter and six months
ended June 30, 2008.
- Sales increased by 104% for the six month period ended June 30, 2008
compared to the same period in 2007. Sales were $12.3 million as
compared to $6.1 million for the same period in 2007, an increase of
- Order backlog grew 31%, showing significant growth, increasing from
$31.7 million at December 31, 2007 to $41.5 million as at June 30,
- Offices opened in Japan and Australia to further global expansion
- IMRIS co-sponsored with Siemens the 6th Annual Magnetom World Summit
in Munich. IMRIS and Siemens continue to strengthen their
relationship on a global basis.
- Subsequent to quarter-end, the Company completed development of the
3 Tesla version of IMRISneuro, a new product line, which will provide
shorter scan times and enhanced image quality.
- IMRIS installed the first operating prototype of IMRIScardio at its
premises and has begun the commercialization of the system.
IMRIScardio continues on schedule with a planned release in early
2009 following the anticipated receipt of the required regulatory
"We now have eight systems in clinical operation and 12 systems in the
delivery phase," said David Graves, Chairman, President and Chief Executive
Officer. "As a result over 1700 procedures have been performed on patients
with IMRISneuro, demonstrating not only growing acceptance of IMRIS' product
in the marketplace but also providing strong validation of our leading-edge
Second Quarter and Six Month Results
Sales for the second quarter of 2008 were $8.2 million, an increase of
230% over the same period in 2007. For the six months ending June 30, 2008
sales increased 104% over the same period in 2007 to $12.3 million. These
increases in revenues were directly attributable to an increase in IMRISneuro
Gross profit for the second quarter and six months ended June 30, 2008
increased by approximately $1.4 million and $1.0 million, respectively as
compared to the same periods in the prior year.
Gross profit percentage for the second quarter of 2008 was 19.1% in 2008
as compared to 6.7% in 2007. For the six months ending June 30, 2008 the gross
profit percentage was 16.9% as compared to 18.1% in 2007. The Company is
focused on improving gross profits and expects margin improvement in the next
twelve months from current levels.
Operating expenses for the second quarter were $5.8 million, an increase
of approximately $1.1 million or 23% over the second quarter of 2007.
Operating expenses were $11.0 million for the six months ended June 30, 2008,
an increase of approximately $2.9 million or 35% higher as compared to the
first six months of 2007. The second quarter and year-to-date increases are
reflected across most major functional areas of the Company. A substantial
amount of the increases in these departmental expenses is attributable to
increased staff levels. IMRIS continued to expand its teams in all functional
areas to address the anticipated growth in demand for its products.
The net loss for the second quarter was $4.1 million, a decrease of
$0.4 million over the second quarter of 2007. The improvement in relative
financial performance was mainly due to higher sales levels and higher gross
profit. The year-to-date loss increased from $7.0 million in 2007 to
$8.5 million in 2008. The increase in the loss was due to the higher operating
expense levels to facilitate the Company's increased commercialization efforts
and was partially offset by higher gross profit.
Since its formation, the Company has focused its efforts on gaining
market acceptance for its products and on ensuring the successful delivery of
each customer installation by developing core competencies across all facets
of the organization. These efforts to date have been rewarded with significant
market acceptance for its IMRISneuro product suite, which is best reflected in
the positive trend in sales results and order backlog.
Following the receipt of a customer purchase order, the delivery and
installation cycle for one of the Company's systems typically ranges from five
to twelve months. In some cases, IMRIS expects the delivery and installation
cycle of the current order backlog to be longer than twelve months, mainly due
to lengthening construction schedules by customers.
Given the number of systems awaiting installation and the high dollar
value of each system, the Company's quarter-over-quarter revenue may vary
significantly in the near term. The Company does believe that overall sales
and gross margin will continue to grow on an annualized basis as a result of
its significant order backlog.
"Our outlook continues to brighten as we build our backlog and execute
our product development strategy to fortify our market leadership position,"
said Mr. Graves. "We've also made strides in developing strong relationships
with prospective customers and strategic partners around the world."
The Company's full financial statements as well as management's
discussion and analysis will be available at www.sedar.com and www.imris.com.
Management will host a conference call to discuss the results at
10 a.m. ET (9 a.m. CT) on Thursday, August 14, 2008. Following management's
presentation, there will be a question-and-answer session for analysts and
institutional investors. To participate in the teleconference, please call
416-644-3419 or 1-800-732-6179. To access the live audio webcast, please visit
IMRIS' website at www.imris.com. A taped rebroadcast will be available to
listeners following the call until midnight (ET) on August 21, 2008. To access
the rebroadcast, please call 416-640-1917 or 1-877-289-8525 and enter passcode
21276208 followed by the number sign. The webcast will also be archived on
IMRIS (TSX: IM) is a global leader in providing fully integrated,
advanced surgical imaging solutions. The company's flagship product,
IMRISneuro, utilizes patented technology that allows a high field MRI scanner
to be moved in to the operating room on demand, providing imaging during the
surgical procedure without compromising patient safety. This unique and
innovative system has been validated by leading neurosurgeons for use in
world-class neuroscience centers.
For more information, visit www.imris.com
This press release may contain or refer to forward-looking information
based on current expectations. In some cases, forward-looking statements can
be identified by terminology such as "anticipate", "may", "expect", "believe",
"prospective", "continue" or the negative of these terms or other similar
expressions concerning matters that are not historical facts. These statements
should not be understood as guarantees of future performance or results. Such
statements involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be materially
different from those implied by such statements. Although such statements are
based on management's reasonable assumptions, there can be no assurance that
actual results will be consistent with such statements. Forward-looking
statements are subject to significant risks and uncertainties, and other
factors that could cause actual results to differ materially from expected
results. These forward-looking statements are made as of the date hereof and
we assume no responsibility to update or revise them to reflect new events or
For further information:
For further information: Investor Relations Contact: Derek Reimer, CA,
Executive Vice President, Finance and Administration and Chief Financial
Officer, IMRIS Inc., Tel: (204) 480-7692, Email: email@example.com; Media
Contact: Susan McLeod, Manager, Marketing Communications, IMRIS Inc., Tel:
(204) 480-7094, Email: firstname.lastname@example.org